Thyroxine-sulfate-T4-Sulfate-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEThyroxine sulfateCat. No.: HY-101406CAS No.: 77074-49-8Synonyms: T4 Sulfate分式: CHINOS分量: 856.93作靶點(diǎn): Thyroid Hormone Receptor; Drug Metabolite; EndogenousMetabolite作通路: Others; Metabolic Enzyme/Protease儲(chǔ)存式: Powder -20C 3 years4C

2、2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 31 mg/mL (36.18 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.1670 mL 5.8348 mL 11.6696 mL5 mM 0.2334 mL 1.1670 mL 2.3339 mL10 mM 0.1167 mL 0.5835 mL 1.1670 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)

3、注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前?qǐng)先配制澄清的儲(chǔ)備液，再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.58 mg/mL (3.01 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)1/2 Mas

4、ter of Small Molecules 您邊的抑制劑師www.MedChemESolubility: 2.58 mg/mL (3.01 mM); Clear solution3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.58 mg/mL (3.01 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Thyroxine sulfate是甲狀腺激素代謝物。IC50 & Target Human Endogenous Metabolite體外研究 Thyroxine sulfate (T4S) is a no

5、rmal component of human serum and amniotic fluid, and it is mostly derivedfrom thyroxine peripherally and accumulates when type I 5-monodeiodinating activity is low in fetuses orinhibited by drugs, such as ipodate 1.體內(nèi)研究 Significant amounts of thyroxine sulfate (T4S) in fetal sheep serum, meconium,

6、bile, and amniotic andallantoic fluids are observed. T4S concentration in amniotic fluid from women at 18-19 weeks of gestation(25.5 ng/dL) is higher than that at 14-15 weeks of gestation (14.3 ng/dL). A significant rise in serum T4S isdetected in hyperthyroid patients 1 day after ingestion of 1 g o

7、f ipodate 1. Thyroxine undergoes significantsulfation in rats, and biliary excretion of T4S is enhanced if its type I deiodination is inhibited 2. Serum T4Slevels are clearly elevated compared with healthy references, and the decreased deiodination by liver D1during critical illness appears to play

8、a role in this increase in serum T4S levels 3.REFERENCES1. Wu SY, et al. Identification of thyroxine-sulfate (T4S) in human serum and amniotic fluid by a novel T4S radioimmunoassay. Thyroid.1992 Summer;2(2):101-5.2. Rutgers M, et al. Effects of propylthiouracil on the biliary clearance of thyroxine

9、(T4) in rats: decreased excretion of 3,5,3-triiodothyronine glucuronide and increased excretion of 3,3,5-triiodothyronine glucuronide and T4 sulfate. Endocrinology. 1989Oct;125(4):2175-86.3. Peeters RP, et al. Increased thyroxine sulfate levels in critically ill patients as a result of a decreased hepatic type Ideiodinase activity. JClin Endocrinol Metab. 2005 Dec;90(12):6460-5.McePdfHeightCaution: Product has not been fully validated for m